As head and neck cancer risks evolve, more treatment options emerge

September 10, 2008

Advances in understanding head and neck cancer over the last decade have led to more treatment options and improved quality of life for patients, according to a review published this week in the New England Journal of Medicine.

The authors are Dong M. Shin, MD, Frances Kelly Blomeyer Distinguished Professor and associate director of Emory University School of Medicine's Winship Cancer Institute, and Robert Haddad, MD, assistant professor of medicine at Harvard Medical School and clinical director of its Head and Neck Oncology Program.

At Winship, Shin is leading a head and neck cancer drug discovery program and conducting clinical trials aimed at preventing head and neck cancers from progressing or recurring. He and his co-workers recently showed that a compound from green tea enhances the effects of a FDA-approved drug (erlotinib) against head and neck cancer cells in animals, suggesting that it could work similarly in humans. The results are published in the September issue of International Journal of Cancer.

The majority of head and neck cancers arise from the soft tissues of the mouth, throat, and voice box. Symptoms can include a sore throat, difficulty swallowing, and a changing voice.

Even successful treatment can result in changes in the appearance of the patient's face. However, over the last decade, techniques have been developed that allow doctors to better preserve organ function in cases of larynx or tongue cancers, Shin says.

Because smoking and alcohol consumption are risk factors, most patients are middle-aged males with a history of smoking and drinking. However, a recent increase in head and neck cancer cases among patients under 40 who do not share those risk factors has alarmed doctors, Shin says.

The increase appears to come from human papillomavirus, the same virus that causes cervical cancer in women, and may be linked with oral sex, he says.

Around 47,000 new cases and 12,000 resulting deaths in the United States are expected this year, making head and neck cancer the fifth deadliest type of cancer, according to the American Cancer Society.

In their review, Shin and Haddad describe:

-- molecular pathways that lead to the development of head and neck cancer
-- refinements in radiation, chemotherapy and surgery allowing doctors to preserve affected tissues and body parts
-- evidence for the link between human papillomavirus and some types of head and neck cancer
-- new therapies designed to target the out-of-control growth circuits in cancer cells

Some of the new therapies, such as erlotinib and cetuximab, work against the signals that come from epidermal growth factor receptor (EGFR), which drives out-of-control growth in head and neck cancer cells. Erlotinib inhibits EGFR's signals inside the cell, while cetuximab consists of antibodies that block the signals from outside the cell.

As an illustration of progress, five-year survival rates for oropharynx and tonsil cancer have increased from 36 percent in the early 1980s to around 54 percent for patients diagnosed in 2000, according to the National Cancer Institute.

Still, Shin says early detection is an important strategy to increase survival.

"More than two-thirds of patients come to doctors with locally and regionally advanced disease, and their prognoses are dismal", he says. "But head and neck cancers are potentially curable when diagnosed at an early stage."

In clinical trials at Winship, Shin is testing drug regimens in an effort to prevent head and neck cancer in patients who have pre-cancerous growths. A separate trial seeks to prevent a second primary tumor in patients who have already had a first.

Source: Emory University

Explore further: Research exploring common biology of cancer, infection and psychiatric disease

Related Stories

Research exploring common biology of cancer, infection and psychiatric disease

November 16, 2017
Nevan Krogan, PhD, is a mapmaker, but the object of his exploration is not any newfound continent or alien world. Instead, he and his colleagues map cells. Rather than cities, towns and interstates, these maps show proteins, ...

How to do a skin cancer body check

November 15, 2017
(HealthDay)—Every year, about 5 million Americans are treated for skin cancer—an abnormal growth of skin cells that most often develops on areas exposed to the sun.

Proton therapy lowers treatment side effects in pediatric head and neck cancer patients

October 23, 2017
Pediatric patients with head and neck cancer can be treated with proton beam therapy (PBT) instead of traditional photon radiation, and it will result in similar outcomes with less impact on quality of life. Researchers from ...

Multidisciplinary model cuts treatment delay in head, neck CA

October 29, 2017
(HealthDay)—For patients with head and neck cancer, a multidisciplinary head and neck clinic model is associated with reduced treatment delay, according to a study published online Oct. 26 in JAMA Otolaryngology—Head ...

For cancer patients with HIV, immunotherapy appears safe

November 7, 2017
A new category of immunotherapies called checkpoint inhibitors that has been highly effective against many different cancers appears safe to use in patients with both advanced malignancies and HIV, a population excluded from ...

Drug yields high response rates for lung cancer patients with harsh mutation

October 18, 2017
A targeted therapy resurrected by the Moon Shots Program at The University of Texas MD Anderson Cancer Center has produced unprecedented response rates among patients with metastatic non-small cell lung cancer that carries ...

Recommended for you

Lung cancer triggers pulmonary hypertension

November 17, 2017
Shortness of breath and respiratory distress often increase the suffering of advanced-stage lung cancer patients. These symptoms can be triggered by pulmonary hypertension, as scientists at the Max Planck Institute for Heart ...

Computer program finds new uses for old drugs

November 16, 2017
Researchers at the Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine have developed a computer program to find new indications for old drugs. The computer program, called DrugPredict, ...

Researchers discover an Achilles heel in a lethal leukemia

November 16, 2017
Researchers have discovered how a linkage between two proteins in acute myeloid leukemia enables cancer cells to resist chemotherapy and showed that disrupting the linkage could render the cells vulnerable to treatment. St. ...

Pharmacoscopy improves therapy for relapsed blood cancer in a first clinical trial

November 16, 2017
Researchers at CeMM and the Medical University of Vienna presented a preliminary report in The Lancet Hematology on the clinical impact of an integrated ex vivo approach called pharmacoscopy. The procedures measure single-cell ...

Wider sampling of tumor tissues may guide drug choice, improve outcomes

November 15, 2017
A new study focused on describing genetic variations within a primary tumor, differences between the primary and a metastatic branch of that tumor, and additional diversity found in tumor DNA in the blood stream could help ...

A new strategy for prevention of liver cancer development

November 14, 2017
Primary liver cancer is now the second leading cause of cancer-related death worldwide, and its incidences and mortality are increasing rapidly in the United Stated. In late stages of the malignancy, there are no effective ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.